Expanding Oncology Pipelines And Emerging Markets Will Unlock Future Success

Published
16 Jul 24
Updated
06 Aug 25
AnalystConsensusTarget's Fair Value
US$28.66
14.0% undervalued intrinsic discount
06 Aug
US$24.65
Loading
1Y
-14.6%
7D
-0.4%

Author's Valuation

US$28.7

14.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 0.60%

Shared on30 Apr 25
Fair value Decreased 1.37%

AnalystConsensusTarget has decreased revenue growth from -1.2% to -1.0%.

Shared on23 Apr 25

Shared on16 Apr 25
Fair value Decreased 2.89%

Shared on09 Apr 25
Fair value Decreased 1.67%

AnalystConsensusTarget has decreased revenue growth from -0.9% to -1.0%.

Shared on02 Apr 25
Fair value Decreased 2.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.064%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Mar 25
Fair value Increased 0.87%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 6.42%

AnalystConsensusTarget has decreased revenue growth from 1.9% to -0.9%.